A comparison between bisphosphonates and other treatments for osteoporosis

Current Pharmaceutical Design

Volumn 16, Issue 27, 2010, Pages 3037-3044

  Le Goff, B ^a,b,c,d   Guillot, P ^b   Glemarec J ^b   Berthelot, J M ^a,b,c   Maugars, Y ^c  

^a Universite de Nantes   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c HÔTEL DIEU   (France)

^d St Vincents Institute   (Australia)

Author keywords

Bisphosphonates; Fractures; Osteoporosis; Teriparatide

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DENOSUMAB; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; TILUDRONIC ACID; ZOLEDRONIC ACID;

ANALGESIA; BONE DENSITY; BONE MINERALIZATION; BONE REMODELING; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG ACTIVITY; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HIP FRACTURE; HUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; VERTEBRA FRACTURE;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG COSTS; DRUG MONITORING; FEMALE; FRANCE; HUMANS; MALE; MEDICATION ADHERENCE; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TERIPARATIDE; THIOPHENES;

EID: 78649850944     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793563563     Document Type: Review

References (79)

1. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19: 80-100.
2. Russell R, Rogers MJ, Frith JC, et al. The pharmacology of bisphosphonates and new insights into their mechanism of action. J Bone Miner Res 1999; 14 (suppl 2): 53-65.
3. Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42 446, a new potent heterocyclic bisphosphonate compound. J Bone Miner Res 1994; 9: 745-51.
4. Gertz B, Holland SD, Kline WF, et al. Studies of the oral bioavailability of Alendronate. Clin Pharmacol 1995; 58: 288-98.
5. Miller PD. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. Clin Ther 2005; 27(4): 361-76.
6. Reid DM, Hosking D, Kendler D, et al. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International. Int J Clin Pract 2008; 62(4): 575-84.
7. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003; 18(6): 1051-6.
8. Black DM, Schwartz AV, Ensrud KE, et al. FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296(24): 2927-38.
9. Ding A, Rosenwasser M. The structural effects of long-term bisphosphonate treatment leading to atypical hip fractures. Paper 241. Presented at the 2010 Annual Meeting of the American Academy of Orthopaedic Surgeons. March 9-13. New Orleans.
10. Borah B, Ritman EL, Dufresne TE, et al. The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover. Bone 2005; 37(1): 1-9.
11. Idris AI, Rojas J, Greig IR, Van't Hof RJ, Ralston SH. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int 2008; 82(3): 191-201.
12. Dicuonzo G, Vincenzi B, Santini D, et al. Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J Interferon Cytokine Res 2003; 23(11): 649-54.
13. Silverman SL, Landesberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med 2009; 122(2 Suppl): S33-45.
14. Khosla S, Burr D, Cauley J, et al. American society for bone and mineral research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the american society for bone and mineral research. J Bone Miner Res 2007; 22(10): 1479-91.
15. Tournis S, Economopoulos D, Lyritis GP. Strontium ranelate: a novel treatment in postmenopausal osteoporosis. Ann N Y Acad Sci 2006; 1092: 403-7.
16. Blake GM, Fogelman I. The correction of BMD measurements for bone strontium content. J Clin Densitom 2007; 10(3): 259-65.
17. Arlot ME, Jiang Y, Genant HK, et al. Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res 2008; 23(2): 215-22.
18. Uzawa T, Hori M, Ejiri S, Ozawa H. Comparison of the effects of intermittent and continuous administration of human parathyroid hormone(1-34) on rat bone. Bone 1995; 16(4): 477-84.
19. Lindsay R, Zhou H, Cosman F, Nieves J, Dempster DW, Hodsman AB. Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res 2007; 22(4): 495-502.
20. Hirano T, Burr DB, Cain RL, Hock JM. Changes in geometry and cortical porosity in adult, ovary-intact rabbits after 5 months treatment with LY333334 (hPTH 1-34). Calcif Tissue Int 2000; 66(6): 456-60.
21. Bai YD, Yang FS, Xuan K, Bai YX, Wu BL. Inhibition of RANK/RANKL signal transduction pathway: a promising approach for osteoporosis treatment. Med Hypotheses 2008; 71(2): 256-8.
22. Matsuo K. Eph and ephrin interactions in bone. Adv Exp Med Biol 2010; 658: 95-103.
23. Ominsky MS, Vlasseros F, Jolette J, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 2010; 25: 948-59.
24. Black DM, Thompson DE. The effect of alendronate therapy on osteoporotic fracture in the vertebral fracture arm of the Fracture Intervention Trial. Int J Clin Pract Suppl 1999; 101: 46-50.
25. Black DM, Thompson DE, Bauer DC, et al. Fracture intervention trial. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000; 85(11): 4118-24.
26. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282(14): 1344-52.
27. Chesnut III CH, Skag A, Christiansen C, et al. Oral ibandronate osteoporosis vertebral fracture trial in north america and europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19(8): 1241-9.
28. Black DM, Delmas PD, Eastell R, et al. HORIZON pivotal fracture trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356(18): 1809-22.
29. Watts NB, Cooper C, Lindsay R, et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 2004; 7: 255-61.
30. Abelson A, Ringe JD, Gold DT, Lange JL, Thomas T. Longitudinal change in clinical fracture incidence after initiation of bisphosphonates. Osteoporos Int., in press.
31. Di Monaco M, Di Monaco R, Manca M, Cavanna A. Functional recovery and length of stay after recurrent hip fracture. Am J Phys Med Rehabil 2002; 81(2): 86-9.
32. Kannegaard PN, van der Mark S, Eiken P, Abrahamsen B. Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival. Age Ageing 2010; 39(2): 203-9.
33. Harvey N, Dennison E, Cooper C. Osteoporosis: impact on health and economics. Nat Rev Rheumatol 2010; 6(2): 99-105.
34. McClung MR, Geusens P, Miller PD, et al. Hip intervention program study group. Effect of risedronate on the risk of hip fracture in elderly women. Hip intervention program study group. N Engl J Med 2001; 344(5): 333-40.
35. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. For the HORIZON recurrent fracture trial. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 2007; 357: nihpa40967.
36. Nevitt MC, Thompson DE, Black DM, et al. Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture intervention trial research group. Arch Intern Med 2000; 160(1): 77-85.
37. Rovetta G, Maggiani G, Molfetta L, Monteforte P. One-month follow-up of patients treated by intravenous clodronate for acute pain induced by osteoporotic vertebral fracture. Drugs Exp Clin Res 2001; 27(2): 77-81.
38. Ohtori S, Akazawa T, Murata Y, et al. Risedronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures. J Clin Neurosci 2010; 17(2): 209-13.
39. Tran de QH, Duong S, Bertini P, Finlayson RJ. Treatment of complex regional pain syndrome: a review of the evidence. Can J Anaesth 2010; 57(2): 149-66.
40. Cook DJ, Guyatt GH, Adachi JD, et al. Quality of life issues in women with vertebral fractures due to osteoporosis. Arth Rheum 2005; 36(6): 750-6.
41. Wallace DJ. Rapid prevention of vertebral fractures associated with osteoporosis. Orthopedics 2005; 28(3): 291-8.
42. Miller PD, Delmas PD, Lindsay R, et al. Open-label study to determine how prior therapy with alendronate or risedronate in postmenopausal women with osteoporosis influences the clinical effectiveness of teriparatide investigators. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 2008; 93(10): 3785-93.
43. Sorensen OH, Crawford GM, Mulder H, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003; 32(2): 120-6.
44. Black DM, Schwartz AV, Ensrud KE, et al. FLEX research group. Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA 2006; 296(24): 2927-38.
45. Rénier JC, Audran M, Séret P, Sécher V. The natural development of osteoporosis. 30 patients with a median follow-up of 11 years. Rev Rhum Mal Osteoartic 1986; 53(7-9): 451-7.
46. Wasnich RD, Bagger YZ, Hosking DJ, et al. Early postmenopausal intervention cohort study group. Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause 2004; 11(6 Pt 1): 622-30.
47. Bauer DC, Garnero P, Hochberg MC, et al. for the fracture intervention research group. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 2006; 21(2): 292-9.
48. Divittorio G, Jackson KL, Chindalore VL, Welker W, Walker JB. Examining the relationship between bone mineral density and fracture risk reduction during pharmacologic treatment of osteoporosis. Pharmacotherapy 2006; 26(1): 104-14.
49. Reginster JY, Felsenberg D, Boonen S, et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a fiveyear, randomized, placebo-controlled trial. Arthritis Rheum 2008; 58(6): 1687-95.
50. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators. JAMA 1999; 282(7): 637-45.
51. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344(19): 1434-41.
52. Cummings SR, San Martin J, McClung MR, et al. FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361(8): 756-65.
53. Cadarette SM, Katz JN, Brookhart MA, Stürmer T, Stedman MR, Solomon DH. Relative effectiveness of osteoporosis drugs for pre venting nonvertebral fracture. Ann Intern Med 2008; 148(9): 637-46.
54. Cranney A, Wells GA, Yetisir E, et al. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int 2009; 20(2): 291-7.
55. Seeman E, Boonen S, Borgström F, et al. Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age. Bone 2010; 46(4): 1038-42.
56. Genant HK, Halse J, Briney WG, Xie L, Glass EV, Krege JH. The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Curr Med Res Opin 2005; 21(7): 1027-34.
57. Siris ES, Harris ST, Eastell R, et al. Continuing outcomes relevant to evista (CORE) investigators. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 2005; 20(9): 1514-24.
58. Meunier PJ, Roux C, Ortolani S, et al. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int 2009; 20(10): 1663-73.
59. Cosman F, Nieves JW, Zion M, Barbuto N, Lindsay R. Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate. J Bone Miner Res 2009; 24(6): 1110-5.
60. Small RE. Uses and limitations of bone mineral density measurements in the management of osteoporosis. MedGenMed 2005; 7(2): 3.
61. Watts NB, Miller PD, Kohlmeier LA, et al. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. J Bone Miner Res 2009; 24(6): 1125-31.
62. Kendler DL, Adachi JD, Josse RG, Slosman DO. Monitoring strontium ranelate therapy in patients with osteoporosis. Osteoporos Int 2009; 20(7): 1101-6.
63. Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009; 60(11): 3346-55.
64. Finkelstein JS, Leder BZ, Burnett SM, et al. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab 2006; 91(8): 2882-7.
65. Woo C, Gao G, Wade S, Hochberg MC. Gastrointestinal side effects in postmenopausal women using osteoporosis therapy: 1- year findings in the POSSIBLE US study. Curr Med Res Opin 2010; 26(4): 1003-9.
66. Solomon DH, Rekedal L, Cadarette SM. Osteoporosis treatments and adverse events. Curr Opin Rheumatol 2009; 21(4): 363-8.
67. Imaz I, Zegarra P, González-Enríquez J, Rubio B, Alcazar R, Amate JM. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and metaanalysis. Osteoporos Int 2009, in press.
68. Schousboe JT, Dowd BE, Davison ML, Kane RL. Association of medication attitudes with non-persistence and non-compliance with medication to prevent fractures. Osteoporos Int 2009, in press.
69. Briesacher BA, Andrade SE, Harrold LR, Fouayzi H, Yood RA. Adoption of once-monthly oral bisphosphonates and the impact on adherence. Am J Med 2010; 123(3): 275-80.
70. Szulc P, Delmas PD. Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int 2008; 19(12): 1683-704.
71. Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 2006; 17(11): 1645-52.
72. Siris ES, Selby PL, Saag KG, Borgström F, Herings RM, Silverman SL. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009; 122(2 Suppl): S3-13.
73. Ziller V, Zimmermann SP, Kalder M, et al. Adherence and persistence in patients with severe osteoporosis treated with teriparatide. Curr Med Res Opin 2010; 26(3): 675-81.
74. Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB. Incidence and mortality of hip fractures in the United States. JAMA 2009; 302(14): 1573-9.
75. Maravic M, Taupin P, Landais P, Roux C. Evolution 2002-2008 of hip fracture incidence in France. 22ème Congrès Français de Rhumatologie, oral communication, novembre 2009, Paris.
76. Tosteson AN, Burge RT, Marshall DA, Lindsay R. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Am J Manag Care 2008; 14(9): 605-15.
77. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003; 9(32): 2643-58.
78. Ruderman EM. Current and future pharmaceutical therapy for rheumatoid arthritis. Curr Pharm Des 2005; 11(5): 671-84.
79. Uludag H. Bisphosphonates as a foundation of drug delivery to bone. Curr Pharm Des 2002; 8(21): 1929-44.